Insurance Barriers to Next-Generation Sequencing Testing in Lung Cancer—When Policy Delays Care

This Viewpoint discusses insurance barriers to next-generation sequencing (NGS) testing for patients with non–small cell lung cancer and proposes policy solutions to address these barriers.

Corresponding Author: Nirmal Choradia, MD, MPH, The University of Oklahoma, 800 NE 10th St, Oklahoma City, OK 73104 (nirmal-choradia@ou.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.